ArticleJournal of nanobiotechnology2026
Fluoroalkylated antimicrobial peptides enables cytosolic delivery and eradication of intracellular Staphylococcus aureus.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Intracellular bacteria survive are difficult to eradicate by conventional antibiotics. Antimicrobial peptides (AMPs) have garnered increasing attention due to their ability to exert broad-spectrum antibacterial effects through various mechanisms. However, they are also unable to effectively penetrate cell membranes to enter the cytoplasm. Fluorination has been proven to effectively enhance the ability of biopeptides to penetrate cell membranes. We designed a fluoroalkylated Omiganan (PFC-OMN) by conjugating a perfluorocarbon tag to a cysteine-terminated Omiganan (OMN) via a disulfide bond, enabling self-assembly into ~ 59 nm nanoparticles and glutathione-triggered release of active OMN in the cytosol. PFC-OMN retained extracellular activity against S. aureus (MIC = 12.5 µM) and exhibited markedly enhanced intracellular bactericidal potency (IMBC₉₉.₉ = 50 µM vs. > 800 µM for unmodified peptide). FITC-PFC-OMN showed 2.6-4.2× higher cellular uptake and broader cytosolic distribution compared with FITC-C-OMN. PFC-OMN displayed low hemolysis (HC₅₀ ≈ 325 µM) and macrophage cytotoxicity (IC₅₀ ≈ 450 µM). In a murine peritonitis model, PFC-OMN significantly reduced intracellular S. aureus counts. These results indicate that fluoroalkylation can enable AMP-mediated eradication of intracellular pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.